ReviewHuman vaccines & immunotherapeutics2016
Chikungunya vaccines in development.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.Nature medicine · 2021Trial
- Mathematical modeling and analysis of the Dengue and Chikungunya co-infection.Scientific reports · 2026Article
- Overview of Chikungunya Virus Pathogenesis, Genome Variation, Epidemiology, and Control.Virus research · 2026Review
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- Modeling within-host Chikungunya virus dynamics with the immune system using semi-analytical approaches.BMC research notes · 2025Article
- A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.NPJ vaccines · 2024Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses · 2024Review
- IgM-specific linear epitopes on the E2 protein for serodiagnosis of Chikungunya.Virus research · 2024Article
- Assessment of heat-killedFrontiers in immunology · 2024Article
- Modelling the transmission of dengue, zika and chikungunya: a scoping review protocol.BMJ open · 2023Article
- Contexts motivating protective behaviours related to Aedes-borne infectious diseases in Curaçao.BMC public health · 2023Article
- Review
- Article
- Current Understanding of the Role of T Cells in Chikungunya, Dengue and Zika Infections.Viruses · 2022Review
- Development and Application of Treatment for Chikungunya Fever.Research and reports in tropical medicine · 2022Review
- The global burden of Chikungunya fever among children: A systematic literature review and meta-analysis.PLOS global public health · 2022Article
- Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.Emerging microbes & infections · 2021Article
- Evaluation of DNA-Launched Virus-Like Particle Vaccines in an Immune Competent Mouse Model of Chikungunya Virus Infection.Vaccines · 2021Article
- Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored. Only two candidates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the current status of vaccine development against chikungunya virus in humans and discusses the diversity of immunization strategies, results of recent human trials and promising vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.